The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects due to a stubborn refusal to pay for innovative new medicines, according to the pharma ...

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a ...